Mycophenolate mofetil

With other immunosuppressants, prevents rejection after allogeneic kidney, heart or liver transplantation in adults and children from three months. This focused label reference does not provide autoimmune-disease or rejection-rescue protocols.

Oral mofetil products must not be exchanged unsupervised with delayed-release mycophenolic acid tablets. Absorption differs; salt-name similarity is not a milligram conversion.

Give twice daily; every IV dose requires an infusion lasting at least two hours, never a bolus. Use IV temporarily when oral treatment cannot be tolerated, starting within 24 hours after transplant for up to 14 days; switch as soon as feasible. Specialist preparation is required.

From three months: kidney 600 mg/m² twice daily, maximum 2 g/day. Heart/liver start 600 mg/m² twice daily; if tolerated, may increase to 900 mg/m² twice daily, maximum 3 g/day. BSA 1.25 to under 1.5 m² permits 750 mg capsules twice daily; BSA ≥ 1.5 m² permits 1 g capsule/tablet twice daily (heart/liver starting doses). No pediatric IV dose is inferred.

For severe chronic kidney-graft impairment, GFR < 25 mL/min/1.73 m², avoid more than 1 g twice daily and monitor closely. Delayed kidney-graft function alone needs no adjustment. If ANC falls below 1,300/µL, interrupt/reduce with diagnostic assessment. These boundaries do not establish a universal renal algorithm for heart/liver recipients.

Prefer an empty stomach; stable recipients may take with food if needed. Swallow tablets/capsules intact. Pharmacist prepares 200 mg/mL suspension; shake and use calibrated dispenser, without mixing into other liquids. Missed dose: take when remembered unless next dose is less than two hours away; then skip, never double.

Aseptic reconstitution and further dilution use 5% dextrose according to the full pharmacy instructions. No concurrent same-catheter admixtures; initiate infusion within four hours after preparation. Hazardous-drug handling and exact dose-dependent preparation remain pharmacy responsibilities.

Hypersensitivity to mofetil, mycophenolic acid or ingredients contraindicates treatment; IV formulation also contraindicated with polysorbate 80 allergy. Serious allergy requires discontinuation and urgent treatment.

Boxed warning covers embryo-fetal toxicity, lymphoma/other cancers and serious infections. Avoid pregnancy exposure when safer alternatives are available; prevention/planning counseling is essential.

Diarrhea, vomiting, abdominal symptoms, leukopenia/anemia and infections are prominent. Combination-regimen trial rates cannot isolate causation. Serious postmarketing marrow, pulmonary, allergy and congenital events have uncertain frequencies.

Give aluminum/magnesium hydroxide antacids and calcium-free phosphate binders such as sevelamer at least two hours AFTER CellCept. PPIs, bile sequestrants, cyclosporine, rifampin and certain antimicrobials can lower exposure; monitor effectiveness. Glucuronidation modifiers such as telmisartan/isavuconazole can alter exposure.

Acyclovir-related antivirals/probenecid can compete with metabolite secretion, especially with renal impairment; monitor adverse effects. Oral contraceptive effectiveness may decrease; additional barrier contraception is required. Do not use absence of a numerical dose rule as permission to combine unsupervised.

MPA concentrations may be useful before/after regimen or interacting-drug changes. No universal therapeutic target, empiric multiplier or fixed interaction-adjustment algorithm is supplied here.

Pregnancy testing immediately before starting and 8–10 days later, then routine follow-up. Acceptable contraception throughout treatment and six weeks afterward; oral pills need a barrier method. Sexually active men and/or female partners should use effective contraception through 90 days after cessation. No blood donation through six weeks or semen donation through 90 days afterward.

Pregnancy exposure markedly increases miscarriage and congenital-malformation risk. Report pregnancy immediately, but do not independently stop graft-protective therapy. Human lactation data are limited and cannot exclude infant risk; weigh feeding benefits, maternal need and alternatives with specialists.

Severe renal impairment increases metabolite exposure; heart/liver evidence is limited. Kidney recipients with severe hepatic parenchymal disease need no adjustment, but other etiologies and heart-recipient hepatic disease lack adequate data. Older recipients require comorbidity/drug review and may face greater infection/GI risks. No dialysis replacement dose is established.

MPA inhibits de-novo guanosine synthesis and lymphocyte proliferation; the immunosuppressive effect is reversible and increases infection risk.

Rapid conversion to MPA; glucuronidation and enterohepatic recirculation influence exposure. MPA is strongly protein bound and elimination mainly occurs as urinary glucuronide. Typical study mean MPA half-life is about 18 hours after oral dosing; dialysis usually removes neither MPA nor metabolite effectively. No plasma half-life determines an individual safe interruption interval.

Label suggests CBC weekly in month one, twice monthly in months two/three, then monthly for the rest of year one. Follow graft/organ function, infection, GI tolerance, inflammatory symptoms and indicated exposure measurements; tailor thereafter. Repeat pregnancy testing/counseling.

Read Medication Guide; preserve the prescribed schedule. Seek urgent care for allergy or severe bleeding/abdominal pain and contact the team for infection or new neurologic symptoms. Limit ultraviolet exposure with clothing/sunscreen. Avoid live vaccines, hazardous powder contact and driving when impaired.

CellCept 500 mg lavender caplet engraved CELLCEPT 500/Roche: 100-tablet bottle NDC 0004-0260-01. Other formulations/brands have distinct identifiers.

250 mg capsules; 500 mg tablets; 35 g powder for 200 mg/mL suspension; 500 mg-equivalent IV single-dose vial (hydrochloride salt). No unsupervised delayed-release mycophenolic-acid substitution.

Selected products: 25°C with permitted 15–30°C excursions; tablets in light-resistant containers. Constituted suspension lasts 60 days, may refrigerate 2–8°C, never freeze. IV prepared solutions must begin infusion within four hours; discard leftovers. Use hazardous-drug handling procedures.